focus -WSS

focus

author：Wikipedia 2025-09-06 04:38:04 - browse：23532

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Adam's Take: Intra

knowledge

WSS

People with substance use disorder deserve online privacy

Readout Newsletter: Illumina, CRISPR, Regeneron

Covid’s new normal has set in amid another rise in cases

Asbestos ban is immediate, but health effects will linger for decades

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Steward Health Care expansion into Malta flopped

knowledge

focus

focus

Hollywood unions extend contract negotiations for actors

Why the quest to eradicate polio has stumbled

How to save PrEP access — and even expand it

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

The cancer drug shortage isn’t new — and neither are the solutions

Steward Health Care expansion into Malta flopped

As demand for Covid shots wanes, Moderna seeks its next success

'A game

In age of alternative facts, a scholarly course on calling out crap

Why the quest to eradicate polio has stumbled

explore

Texas board proposes rules on abortion law emergency exemption

Neurocrine congenital adrenal hyperplasia trial succeeds

Yancopoulos of Regeneron works to expand Dupixent success

Cancer, immunology, HIV research ensnared in fetal tissue politics

Patients, doctors press FTC to beef up hospital merger scrutiny

Midwives could help bridge maternal health disparities in the U.S.

hotspot

hotspot

knowledge

focus